CD47 expression is increased in several cancertypes including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL),non-Hodgkin lymphoma (NHL), primary effusion lymphoma, multiple myeloma, leiomyosarcoma,and bladder cancer, and targeting of CD47 on cancer cells with an anti-CD47 blockingantibody can promote phagocytosis by macrophages in vitro (Chan et al., 2009; Jaiswal et al.,2009; Majeti et al., 2009; Chao et al., 2010a; Edris et al., 2012). This evidence concerns the gene CD47 and plasma cell myeloma.